In Other News

• Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead

• Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead

• Bedside CSF Monitor Detects Early Infection in Fluid Drains

• Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer

• Saliva-Based Test Detects Biochemical Signs of Sleep Loss

• Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection

• Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers

• Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers

• Blood-Based Method Tracks Gene Activity in the Living Brain

• Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer

• Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease

• FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors

• Simple Cytogenetic Method Could Improve Classification of ALL Subtypes

• Diazyme Laboratories Acquires Carolina Liquid Chemistries

• Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia

• Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response

• Partnership Expands Access to Alzheimer’s Blood Tests in Latin America and Caribbean

• Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection

• Multi-Cancer Test Boosts Detection When Added to Standard Screening

• Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia

• Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer

• Study Points to Autoimmune Pathway Behind Long COVID Symptoms

• AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines